TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 42)

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.4 CURRENCY

TABLE 1 STANDARD CURRENCY CONVERSION RATES

1.5 LIMITATIONS

1.6 STAKEHOLDERS

1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 47)

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 2 PRIMARY SOURCES

2.1.2.1 Key data from primary sources

2.1.2.2 Key industry insights

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.2 MARKET SIZE ESTIMATION

FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION

FIGURE 6 MARKET SIZE APPROACH

FIGURE 7 TOP-DOWN APPROACH

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 8 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ANALYSIS

2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 57)

FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD BILLION)

FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD BILLION)

FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020 VS. 2025 (USD BILLION)

FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2020 VS. 2025 (USD BILLION)

FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 61)

4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW

FIGURE 14 INCREASING DEMAND FOR TARGETED THERAPIES AND PERSONALIZED MEDICINE IN THE PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH

4.2 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER (2019)

FIGURE 15 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES COMMANDED THE LARGEST SHARE OF THE APAC COMPANION DIAGNOSTICS MARKET IN 2019

4.3 REGIONAL MIX: COMPANION DIAGNOSTICS MARKET

FIGURE 16 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD

4.4 COMPANION DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES

FIGURE 17 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

4.5 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

FIGURE 18 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 65)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 19 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Advantages of companion diagnostics

5.2.1.2 Growing need for targeted therapy

5.2.1.3 Growing importance of personalized medicine

FIGURE 20 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008�2016

5.2.1.4 Increasing global incidence of cancer

FIGURE 21 GLOBAL CANCER INCIDENCE, 2008�2030

5.2.1.5 Growing application areas of companion diagnostics

5.2.2 RESTRAINTS

5.2.2.1 High cost of companion diagnostic tests

5.2.2.2 Uncertain reimbursement scenario in different regions

TABLE 2 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE

5.2.3 OPPORTUNITIES

5.2.3.1 Increasing demand for next-generation sequencing

TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS

5.2.3.2 Growing significance of companion diagnostics in drug development

5.2.3.3 Increasing number of clinical trials

TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS

5.2.4 CHALLENGES

5.2.4.1 Impact of the COVID-19 pandemic

5.2.4.2 Shortage of trained professionals

6 INDUSTRY INSIGHTS (Page No. - 74)

6.1 INTRODUCTION

6.2 INDUSTRY TRENDS

6.2.1 IMPACT OF THE COVID-19 PANDEMIC ON THE COMPANION DIAGNOSTICS MARKET

FIGURE 22 IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET

6.2.2 GROWING FOCUS ON LIQUID BIOPSY IN COMPANION DIAGNOSTICS

6.2.3 INCREASING COLLABORATIONS

TABLE 5 RECENT COLLABORATIONS IN THE COMPANION DIAGNOSTICS MARKET

6.3 REGULATORY ANALYSIS

6.3.1 NORTH AMERICA

6.3.1.1 US

TABLE 6 US: CLASSIFICATION OF MEDICAL DEVICES

FIGURE 23 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR COMPANION DIAGNOSTIC PRODUCTS

6.3.1.2 Canada

6.3.2 EUROPE

6.3.3 ASIA PACIFIC

6.3.3.1 Australia

6.3.3.2 Japan

TABLE 7 JAPAN: CLASSIFICATION OF MEDICAL DEVICES

6.3.3.3 China

TABLE 8 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

6.3.3.4 India

FIGURE 24 INDIA: REGULATORY PROCESS FOR IVD DEVICES

TABLE 9 INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

6.3.4 BRAZIL

6.4 PRODUCT PIPELINE ANALYSIS

TABLE 10 COMPANION DIAGNOSTICS PRODUCT PIPELINE ANALYSIS, BY MARKET PLAYER: CURRENT MARKET SCENARIO

7 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 87)

7.1 INTRODUCTION

TABLE 11 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 12 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

7.2 IMPACT OF COVID-19 ON THE DEMAND AND SUPPLY OF COMPANION DIAGNOSTIC PRODUCTS & SERVICES

7.3 ASSAYS, KITS, AND REAGENTS

7.3.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT THE ADOPTION OF ASSAYS & KITS

TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 14 COMPANION DIAGNOSTIC ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2020�2025 (USD MILLION)

7.4 SOFTWARE & SERVICES

7.4.1 NEED FOR EFFECTIVE DATA MANAGEMENT SOFTWARE WITHIN LABORATORIES TO CONTRIBUTE TO MARKET GROWTH

TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020�2025 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 94)

8.1 INTRODUCTION

TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

8.2 IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTIC TECHNOLOGY MARKET

8.3 POLYMERASE CHAIN REACTION (PCR)

8.3.1 GROWING APPLICATIONS OF PCR TECHNOLOGIES IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH

TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR THE DETECTION OF RAS/BRAF MUTATION

TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE IN THE MARKET

TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2020�2025 (USD MILLION)

8.4 NEXT-GENERATION SEQUENCING (NGS)

8.4.1 NGS SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE IN THE MARKET

TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2020�2025 (USD MILLION)

8.5 IN SITU HYBRIDIZATION (ISH)

8.5.1 ADVANCEMENTS IN ISH AND ITS DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH

TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE IN THE MARKET

TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2020�2025 (USD MILLION)

8.6 IMMUNOHISTOCHEMISTRY (IHC)

8.6.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES IN CDX TO SUPPORT GROWTH IN THIS SEGMENT

TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE IN THE MARKET

TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2020�2025 (USD MILLION)

8.7 OTHER TECHNOLOGIES

TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020�2025 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY INDICATION (Page No. - 111)

9.1 INTRODUCTION

TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

9.2 IMPACT OF COVID-19 ON VARIOUS INDICATIONS IN THE COMPANION DIAGNOSTICS MARKET

9.3 CANCER

FIGURE 25 BREAST CANCER TO DOMINATE THE COMPANION DIAGNOSTICS MARKET FOR CANCER DURING THE FORECAST PERIOD

TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2020�2025 (USD MILLION)

9.3.1 BREAST CANCER

9.3.1.1 Breast cancer is the most common cancer among women�a key factor contributing to the large share of this market segment

TABLE 40 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 41 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2020�2025 (USD MILLION)

9.3.2 LUNG CANCER

9.3.2.1 Growing demand for therapeutic drugs and their high efficacy in the treatment of lung cancer to increase CDX adoption

FIGURE 26 GLOBAL LUNG CANCER INCIDENCE, 2012�2030

TABLE 42 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 43 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2020�2025 (USD MILLION)

9.3.3 COLORECTAL CANCER

9.3.3.1 Growing need for molecular profiling of primary tumors in colorectal cancer to drive growth in this market segment

TABLE 44 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 45 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020�2025 (USD MILLION)

9.3.4 MELANOMA

9.3.4.1 Growing incidence of melanoma drives the demand for companion diagnostics

TABLE 46 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 47 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2020�2025 (USD MILLION)

9.3.5 GASTRIC CANCER

9.3.5.1 Increasing focus of market players on the development of tests and kits for gastric cancer indications to drive market growth

TABLE 48 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 49 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2020�2025 (USD MILLION)

9.4 INFECTIOUS DISEASES

9.4.1 GROWING FOCUS OF COMPANION DIAGNOSTIC PLAYERS ON ORPHAN INDICATIONS TO PROPEL THE GROWTH OF THIS SEGMENT

TABLE 50 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 51 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020�2025 (USD MILLION)

9.5 CARDIOVASCULAR DISEASES

9.5.1 GROWING DEMAND FOR TARGETED THERAPIES DUE TO HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE GROWTH

TABLE 52 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 53 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020�2025 (USD MILLION)

9.6 NEUROLOGICAL DISEASES

9.6.1 GROWING NUMBER OF DIAGNOSTIC TECHNOLOGIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES TO BOOST THE ADOPTION OF COMPANION DIAGNOSTICS

TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 55 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2020�2025 (USD MILLION)

9.7 OTHER INDICATIONS

TABLE 56 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 57 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020�2025 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY END USER (Page No. - 136)

10.1 INTRODUCTION

TABLE 58 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 59 COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

10.2 IMPACT OF COVID-19 ON THE END USERS IN THE COMPANION DIAGNOSTICS MARKET

10.3 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

10.3.1 WIDE USAGE OF CDX IN PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH

TABLE 60 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 61 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020�2025 (USD MILLION)

10.4 REFERENCE LABORATORIES

10.4.1 GROWING INCIDENCE OF AND RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH

TABLE 62 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 63 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020�2025 (USD MILLION)

10.5 CONTRACT RESEARCH ORGANIZATIONS

10.5.1 CROS OFFER A COMPLETE RANGE OF COMPANION DIAGNOSTIC SERVICES TO TARGETED THERAPY-RELATED CLINICAL TRIALS

TABLE 64 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 65 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020�2025 (USD MILLION)

10.6 OTHER END USERS

TABLE 66 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 67 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2020�2025 (USD MILLION)

11 COMPANION DIAGNOSTICS MARKET, BY REGION (Page No. - 147)

11.1 INTRODUCTION

FIGURE 27 GEOGRAPHIC SNAPSHOT: CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

TABLE 68 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017�2019 (USD MILLION)

TABLE 69 COMPANION DIAGNOSTICS MARKET, BY REGION, 2020�2025 (USD MILLION)

11.2 IMPACT OF COVID-19 ON VARIOUS REGIONS IN THE COMPANION DIAGNOSTICS MARKET

11.3 NORTH AMERICA

FIGURE 28 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT

TABLE 70 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 71 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020�2025 (USD MILLION)

TABLE 72 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.3.1 US

11.3.1.1 US is the largest market for companion diagnostics in North America

TABLE 82 US: KEY MACROINDICATORS

TABLE 83 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 84 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 85 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 89 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 90 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 92 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.3.2 CANADA

11.3.2.1 Government initiatives to promote companion diagnostics in various indications to drive market growth in Canada

TABLE 93 CANADA: KEY MACROINDICATORS

TABLE 94 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 95 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 96 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4 EUROPE

TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 105 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020�2025 (USD MILLION)

TABLE 106 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.1 GERMANY

11.4.1.1 Germany is a major market for pharmaceutical and biotechnology products in Europe

TABLE 116 GERMANY: KEY MACROINDICATORS

TABLE 117 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 118 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 119 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.2 UK

11.4.2.1 Growth in the country�s life science industry and increasing research are key factors driving market growth in the UK

TABLE 127 UK: KEY MACROINDICATORS

TABLE 128 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 129 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 134 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 135 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 136 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 137 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.3 SWITZERLAND

11.4.3.1 Switzerland boasts a strong research-oriented pharma industry, a key factor supporting market growth

TABLE 138 SWITZERLAND: KEY MACROINDICATORS

TABLE 139 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.4 FRANCE

11.4.4.1 Increasing government funding for genomics and personalized therapeutics R&D is driving market growth

TABLE 149 FRANCE: KEY MACROINDICATORS

TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.5 ITALY

11.4.5.1 Growing disease prevalence has contributed to the demand for better, more powerful therapeutics in Italy

TABLE 160 ITALY: KEY MACROINDICATORS

TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 170 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.6 SPAIN

11.4.6.1 Medical institutes in Spain are increasingly focusing on cancer biomarker research

TABLE 171 SPAIN: KEY MACROINDICATORS

TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 180 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 181 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.4.7 REST OF EUROPE

TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 190 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 191 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.5 ASIA PACIFIC

FIGURE 29 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT

TABLE 192 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 193 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020�2025 (USD MILLION)

TABLE 194 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 195 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 196 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 197 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 198 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 199 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 200 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 201 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 202 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 203 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.5.1 JAPAN

11.5.1.1 Japan holds the second largest share of the market in APAC

TABLE 204 JAPAN: KEY MACROINDICATORS

TABLE 205 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 206 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 207 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 208 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 209 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 210 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 211 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 212 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.5.2 CHINA

11.5.2.1 China is one of the most prominent research markets, worldwide

TABLE 215 CHINA: KEY MACROINDICATORS

TABLE 216 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 217 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 218 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 219 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 220 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 221 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 222 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 223 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 224 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 225 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.5.3 INDIA

11.5.3.1 Government initiatives to tackle the growing burden of cancer are expected to increase the adoption of CDX in the country

TABLE 226 INDIA: KEY MACROINDICATORS

TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 234 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 235 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 236 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.5.4 AUSTRALIA

11.5.4.1 Growing geriatric population in Australia has resulted in initiatives to enhance healthcare access and infrastructure

TABLE 237 AUSTRALIA: KEY MACROINDICATORS

TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 244 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 245 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 246 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 247 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.5.5 REST OF ASIA PACIFIC

TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 254 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 255 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 256 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 257 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.6 LATIN AMERICA

TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017�2019 (USD MILLION)

TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020�2025 (USD MILLION)

TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 266 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 267 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 268 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 269 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.6.1 BRAZIL

11.6.1.1 Brazil dominates the Latin American companion diagnostics market

TABLE 270 BRAZIL: KEY MACROINDICATORS

TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 276 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 277 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 278 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 279 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 280 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.6.2 MEXICO

11.6.2.1 Mexico is emerging as a prominent medical tourism hub

TABLE 281 MEXICO: KEY MACROINDICATORS

TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 286 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 287 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 288 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 289 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 290 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 291 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.6.3 REST OF LATIN AMERICA

TABLE 292 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 293 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 294 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 295 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 296 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 297 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 298 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 299 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 300 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 301 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

11.7 MIDDLE EAST & AFRICA

11.7.1 RISING CANCER INCIDENCE RATE HAS ATTRACTED STAKEHOLDER ATTENTION TO REGIONAL MARKETS IN MEA

TABLE 302 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017�2019 (USD MILLION)

TABLE 303 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020�2025 (USD MILLION)

TABLE 304 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017�2019 (USD MILLION)

TABLE 305 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020�2025 (USD MILLION)

TABLE 306 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017�2019 (USD MILLION)

TABLE 307 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020�2025 (USD MILLION)

TABLE 308 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017�2019 (USD MILLION)

TABLE 309 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020�2025 (USD MILLION)

TABLE 310 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017�2019 (USD MILLION)

TABLE 311 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020�2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 262)

12.1 OVERVIEW

FIGURE 30 KEY DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET BETWEEN JANUARY 2017 AND MAY 2020

TABLE 312 GROWTH STRATEGY MATRIX (2017�2020)

12.2 MARKET SHARE ANALYSIS

FIGURE 31 COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019

12.3 COMPETITIVE LEADERSHIP MAPPING, 2019

12.4 VENDOR INCLUSION CRITERIA

12.5 VENDOR DIVE

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 EMERGING COMPANIES

12.5.4 PERVASIVE PLAYERS

FIGURE 32 COMPANION DIAGNOSTICS MARKET COMPETITIVE LEADERSHIP MAPPING, 2019

12.6 COMPETITIVE SITUATIONS AND TRENDS

FIGURE 33 PRODUCT LAUNCHES & APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2017 & 2020

TABLE 313 PRODUCT LAUNCHES & APPROVALS, 2017�2020

12.6.1 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS

TABLE 314 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS, 2017�2020

12.6.2 ACQUISITIONS

TABLE 315 ACQUISITIONS, 2017�2020

TABLE 316 EXPANSIONS, 2017-2020

13 COMPANY PROFILES (Page No. - 272)

13.1 F. HOFFMANN-LA ROCHE AG

FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

13.2 AGILENT TECHNOLOGIES, INC.

FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT

13.3 QIAGEN N.V.

FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT

13.4 THERMO FISHER SCIENTIFIC, INC.

FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

13.5 ABBOTT LABORATORIES, INC.

FIGURE 38 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT

13.6 ALMAC GROUP

13.7 DANAHER CORPORATION

FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT

13.8 ILLUMINA INC.

FIGURE 40 ILLUMINA INC.: COMPANY SNAPSHOT

13.9 BIOM�RIEUX SA

FIGURE 41 BIOM�RIEUX SA: COMPANY SNAPSHOT

13.10 MYRIAD GENETICS, INC.

FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

13.11 SYSMEX CORPORATION

FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT

13.12 ABNOVA CORPORATION

13.13 GUARDANT HEALTH, INC.

FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT

13.14 ICON PLC

FIGURE 45 ICON PLC: COMPANY SNAPSHOT

13.15 BIOGENEX LABORATORIES, INC.

13.16 OTHER COMPANIES

13.16.1 INVIVOSCRIBE TECHNOLOGIES

13.16.2 ARCHERDX, INC.

13.16.3 NG BIOTECH

13.16.4 Q� SOLUTIONS

13.16.5 AMOY DIAGNOSTICS CO., LTD.

14 ADJACENT AND RELATED MARKETS CHAPTER (Page No. - 316)

14.1 INTRODUCTION

14.2 MOLECULAR DIAGNOSTICS MARKET

14.2.1 MARKET DEFINITION

14.2.2 LIMITATIONS

14.2.3 MARKET OVERVIEW

14.3 MOLECULAR DIAGNOSTICS MARKET, BY REGION

TABLE 317 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016�2023 (USD MILLION)

14.4 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

TABLE 318 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016�2023 (USD MILLION)

14.4.1 POLYMERASE CHAIN REACTION (PCR)

TABLE 319 MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY REGION, 2016�2023 (USD MILLION)

14.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

TABLE 320 MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2016�2023 (USD MILLION)

14.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)

TABLE 321 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, BY REGION, 2016�2023 (USD MILLION)

14.4.4 IN SITU HYBRIDIZATION

TABLE 322 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2016�2023 (USD MILLION)

14.4.5 DNA MICROARRAY

TABLE 323 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2016-2023 (USD MILLION)

14.4.6 OTHER TECHNOLOGIES

TABLE 324 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016�2023 (USD MILLION)

14.5 MOLECULAR DIAGNOSTICS MARKET, BY END USER

TABLE 325 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016�2023 (USD MILLION)

14.5.1 HOSPITAL & ACADEMIC LABORATORIES

TABLE 326 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL & ACADEMIC LABORATORIES, BY REGION, 2016�2023 (USD MILLION)

14.5.2 REFERENCE LABORATORIES

TABLE 327 MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2016�2023 (USD MILLION)

14.5.3 OTHER END USERS

TABLE 328 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2016�2023 (USD MILLION)

15 APPENDIX (Page No. - 324)

15.1 INSIGHTS FROM INDUSTRY EXPERTS

15.2 DISCUSSION GUIDE

15.3 KNOWLEDGE STORE: MARKETSANDMARKETS� SUBSCRIPTION PORTAL

15.4 AVAILABLE CUSTOMIZATIONS

15.5 RELATED REPORTS

15.6 AUTHOR DETAILS